Laboratories of the International Health Division, the Rockefeller Foundation, New York.
J Exp Med. 1937 Jan 31;65(2):251-9. doi: 10.1084/jem.65.2.251.
Human influenza virus cultivated in tissue culture medium may be administered subcutaneously or intradermally to human individuals without causing evidence of infection. Subjects so treated develop a good titer of circulating antibodies effective against mouse passage virus and, if antibodies were previously present, vaccination stimulates the production of more antibody. The antibodies so induced persist for at least 5 months, although in this period of time some decline in titer may have begun. The antibody response to vaccination parallels both in extent and persistence that occurring as a result of the naturally acquired disease. The available data do not enable one to evaluate the effect of vaccination in preventing human infection with influenza. It seems not unlikely that the increase in circulating antibody will be accompanied by an increased ability to combat the natural infection.
在组织培养介质中培养的人流感病毒可以通过皮下或皮内途径给予人类个体而不引起感染的证据。接受这种治疗的受试者会产生针对鼠传病毒的循环抗体的良好效价，并且如果之前存在抗体，疫苗接种会刺激更多抗体的产生。诱导的抗体至少持续 5 个月，尽管在此期间效价可能已经开始下降。疫苗接种引起的抗体反应在程度和持久性上与自然获得性疾病的反应相似。现有数据使人无法评估疫苗接种在预防人类流感感染方面的效果。增加循环抗体似乎不太可能伴随着对抗自然感染的能力的提高。
